DE69821011T3 - Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen - Google Patents

Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen Download PDF

Info

Publication number
DE69821011T3
DE69821011T3 DE69821011T DE69821011T DE69821011T3 DE 69821011 T3 DE69821011 T3 DE 69821011T3 DE 69821011 T DE69821011 T DE 69821011T DE 69821011 T DE69821011 T DE 69821011T DE 69821011 T3 DE69821011 T3 DE 69821011T3
Authority
DE
Germany
Prior art keywords
csf
arteries
collateral
growth
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69821011T
Other languages
German (de)
English (en)
Other versions
DE69821011T2 (de
DE69821011D1 (de
Inventor
R. Ivo BUSCHMANN
Wolfgang Schaper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227431&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69821011(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Application granted granted Critical
Publication of DE69821011D1 publication Critical patent/DE69821011D1/de
Publication of DE69821011T2 publication Critical patent/DE69821011T2/de
Publication of DE69821011T3 publication Critical patent/DE69821011T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Photolithography (AREA)
DE69821011T 1997-10-02 1998-10-01 Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen Expired - Lifetime DE69821011T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97117155 1997-10-02
EP97117155 1997-10-02
PCT/EP1998/006233 WO1999017798A1 (en) 1997-10-02 1998-10-01 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

Publications (3)

Publication Number Publication Date
DE69821011D1 DE69821011D1 (de) 2004-02-12
DE69821011T2 DE69821011T2 (de) 2004-11-18
DE69821011T3 true DE69821011T3 (de) 2009-01-08

Family

ID=8227431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69821011T Expired - Lifetime DE69821011T3 (de) 1997-10-02 1998-10-01 Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen

Country Status (9)

Country Link
US (4) US7507705B2 (https=)
EP (1) EP1019082B2 (https=)
JP (2) JP4891477B2 (https=)
AT (1) ATE257392T1 (https=)
CA (1) CA2304354A1 (https=)
DE (1) DE69821011T3 (https=)
DK (1) DK1019082T4 (https=)
ES (1) ES2221212T5 (https=)
WO (1) WO1999017798A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69821011T3 (de) 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
WO2000060054A1 (en) * 1999-04-06 2000-10-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
AU2001261737A1 (en) * 2000-05-18 2001-11-26 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis using monocytes
CA2412436C (en) * 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
DE10033219A1 (de) * 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
WO2002022163A1 (en) * 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
FR2834898B1 (fr) * 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique du g-csf, du gm-csf et du scf
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
KR20050091720A (ko) * 2002-12-13 2005-09-15 히사요시 후지와라 비허혈성 심부전 치료용 의약 조성물
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7166458B2 (en) * 2003-01-07 2007-01-23 Bio Tex, Inc. Assay and method for analyte sensing by detecting efficiency of radiation conversion
EP1527785A1 (en) * 2003-10-27 2005-05-04 Ludwig-Maximilians-Universität München Use of G-CSF for treating ischemia
CN1886150B (zh) * 2003-10-27 2010-05-26 学校法人庆应义塾 含有g-csf的成纤维细胞动员剂及创伤治疗剂
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
AU2004288715A1 (en) * 2003-11-06 2005-05-26 Celgene Corporation Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders
WO2005084702A1 (ja) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
WO2006096931A1 (en) * 2005-03-18 2006-09-21 The University Of Queensland Renal repair and regeneration
CA2663273A1 (en) 2006-09-15 2008-03-20 Kintan Pty Ltd Methods and compositions for promoting organ development
ES2650224T3 (es) 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
RU2376995C1 (ru) * 2008-09-26 2009-12-27 Евгений Владимирович Пыхтин Способ лечения ишемии нижних конечностей
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
JP2014520873A (ja) 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン ｃ−Ｆｍｓアンタゴニストの使用
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
SG11201507871XA (en) 2013-04-12 2015-10-29 Morphosys Ag Antibodies targeting m-csf
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
US12290564B2 (en) * 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
US12293330B2 (en) 2021-10-27 2025-05-06 Express Scripts Strategic Development, Inc. Product packing system and method
US12293315B2 (en) 2021-10-27 2025-05-06 Express Scripts Strategic Development, Inc. System and method for load balancing carrier devices among stations in a packing system

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3629640A1 (de) 1986-08-30 1988-03-03 Behringwerke Ag Verwendung monoklonaler antikoerper zur therapie von tumoren
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5047504A (en) * 1987-04-28 1991-09-10 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US4980281A (en) 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
FI924778A0 (fi) 1991-02-22 1992-10-21 Amgen Inc Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning
US5466781A (en) * 1991-05-24 1995-11-14 Chiron Therapeutics Process for purifying bacterially produced M-CSF
JP3954004B2 (ja) 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
JP3954005B2 (ja) 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
JPH07188048A (ja) 1993-12-27 1995-07-25 Green Cross Corp:The 血管内膜肥厚改善剤
AUPM375094A0 (en) 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules and methods for assaying cytokine function
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5570372A (en) 1995-11-08 1996-10-29 Siemens Rolm Communications Inc. Multimedia communications with system-dependent adaptive delays
EP0941116B1 (en) * 1996-11-01 2005-01-19 Ark Therapeutics Limited Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
CA2284922A1 (en) * 1997-04-04 1998-10-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
DE69821011T3 (de) * 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
WO2000060054A1 (en) 1999-04-06 2000-10-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
DE10033219A1 (de) 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
JP4799803B2 (ja) * 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
WO2002022163A1 (en) 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
US6544543B1 (en) * 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue
ATE422901T1 (de) 2001-03-12 2009-03-15 Inst Of Gene And Brain Science Granulocyte-macrophage colony-stimulating factor (gm-csf) als heilmittel für nervenschäden
US20020131959A1 (en) * 2001-03-14 2002-09-19 Ivo Buschmann Means and methods for the modulation of arteriogenesis
WO2002099081A2 (en) 2001-06-07 2002-12-12 Quark Biotech, Inc. Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
FR2834898B1 (fr) 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique du g-csf, du gm-csf et du scf
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20060142102A1 (en) * 2004-12-23 2006-06-29 Mijo Radocaj Pulley assembly
US7569545B2 (en) * 2005-05-20 2009-08-04 Academia Sinica Methods of increasing neurotrophic factor expression
US7618938B2 (en) * 2007-02-07 2009-11-17 Academia Sinica Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
WO2008137571A1 (en) * 2007-05-01 2008-11-13 Florida Atlantic University Methods of treating neurodegenerative diseases

Also Published As

Publication number Publication date
CA2304354A1 (en) 1999-04-15
EP1019082B1 (en) 2004-01-07
DK1019082T3 (da) 2004-05-10
EP1019082B2 (en) 2008-06-04
US7507705B2 (en) 2009-03-24
JP4891477B2 (ja) 2012-03-07
US20090093412A1 (en) 2009-04-09
JP2009132744A (ja) 2009-06-18
JP2001518517A (ja) 2001-10-16
ES2221212T3 (es) 2004-12-16
ES2221212T5 (es) 2008-12-01
US20090093413A1 (en) 2009-04-09
DE69821011T2 (de) 2004-11-18
DK1019082T4 (da) 2008-10-27
US20030147862A1 (en) 2003-08-07
WO1999017798A1 (en) 1999-04-15
EP1019082A1 (en) 2000-07-19
US20090191146A1 (en) 2009-07-30
ATE257392T1 (de) 2004-01-15
US8101188B2 (en) 2012-01-24
DE69821011D1 (de) 2004-02-12

Similar Documents

Publication Publication Date Title
DE69821011T3 (de) Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
Kurek et al. The role of leukemia inhibitory factor in skeletal muscle regeneration
DE69333321T2 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE68905438T2 (de) Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose.
DE69811348T2 (de) Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen
US20050112061A1 (en) Use of a VEGF antagonist in combination with radiation therapy
EP3154551B1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
US20050196340A1 (en) Use of a VEGF antagonist in combination with radiation therapy
DE60129472T2 (de) Behandlung von hypoxya/ischaemia blutflusswiderstand mit beta-interferon
JP2784401B2 (ja) 慢性骨髄性白血病の治療方法
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CN100518817C (zh) 恢复造血功能的治疗剂和组合物及其用途
DE19711795C2 (de) Verwendung von Cyclosporin für die Behandlung von Myokardinfarkten und deren Folgen
CN117018202A (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
DE60020635T2 (de) Chronische myeloide Leukämie Therapie
DE69428276T2 (de) Insulinähnlicher wachstumfaktor ii als antitumormittel
JPH04500678A (ja) 病巣内部で組換え型ヒトαインターフェロンを用いる偏平上皮癌の治療
US7615538B2 (en) Method for therapy of rheumatoid arthritis
JPH0429936A (ja) 悪性脳腫瘍治療用医薬組成物
CI Cl< KZI

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WIS, DE